This hypothesis proposes that CD38, the primary NAD+-consuming enzyme, represents a more effective therapeutic target than NAD+ precursor supplementation for preventing poly(ADP-ribose) polymerase (PARP1)-driven metabolic catastrophe. CD38 accounts for approximately 80-90% of cellular NAD+ consumption through its NADase and ADP-ribosyl cyclase activities, creating a metabolic bottleneck that limits NAD+ availability for essential processes including SIRT1/3-mediated mitochondrial biogenesis and
This hypothesis proposes that NAD+ precursor supplementation can restore neuronal ketone body utilization by activating SIRT1-mediated upregulation of MCT1 (monocarboxylate transporter 1). In neurodegenerative conditions, chronic PARP1 activation depletes cellular NAD+ pools, leading to reduced SIRT1 activity and subsequent downregulation of MCT1 expression. This creates a metabolic catastrophe where neurons lose their ability to efficiently transport and utilize ketone bodies as an alternative
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Unspecified Mechanismmetabolomics
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
7/11
dimensions won
CD38 Inhibition to Preserve NAD+ Pools a
7/11
dimensions won
NAD+-Dependent Upregulation of MCT1 Expr
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.65
0.65
Evidence
0.00
0.00
Novelty
0.00
0.00
Feasibility
0.00
0.00
Impact
0.00
0.00
Druggability
0.80
0.80
Safety
0.50
0.50
Competition
0.60
0.60
Data
0.65
0.65
Reproducible
0.55
0.55
KG Connect
0.50
0.50
Score Breakdown
Dimension
CD38 Inhibition to Preserve NA
NAD+-Dependent Upregulation of
Mechanistic
0.650
0.650
Evidence
0.000
0.000
Novelty
0.000
0.000
Feasibility
0.000
0.000
Impact
0.000
0.000
Druggability
0.800
0.800
Safety
0.500
0.500
Competition
0.600
0.600
Data
0.650
0.650
Reproducible
0.550
0.550
KG Connect
0.500
0.500
Evidence
CD38 Inhibition to Preserve NAD+ Pools and Prevent PARP1-Med
No evidence citations yet
NAD+-Dependent Upregulation of MCT1 Expression to Restore Ne
No evidence citations yet
Debate Excerpts
CD38 Inhibition to Preserve NAD+ Pools and Prevent
4 rounds · quality: 0.50
Theorist
# Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration
---
## Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
**Title:** MCT1 transporter upregu...
Skeptic
# Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration
I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanati...
Domain Expert
# Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration
## Executive Summary
All seven hypotheses face significant translational barriers. The metabolomics field provides genuine...
# Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration
---
## Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
**Title:** MCT1 transporter upregu...
Skeptic
# Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration
I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanati...
Domain Expert
# Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration
## Executive Summary
All seven hypotheses face significant translational barriers. The metabolomics field provides genuine...